Regulatory Hycamtin(Oral) PMS
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
Lung Cancer, Small Cell
DRUG: Topotecan
Occurrence of adverse events after Topotecan administration, 9 months
Occurrence of unexpected adverse event or adverse drug reaction, 9 months|Occurrence of serious adverse event or adverse drug reation, 9 months
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information

Topotecan will be administered as described the prescribing information or by physician's decision.